91AV

Professor Christopher Jackson is Equinor Professor of Basin Analysis at Imperial College. Having completed his BSc (1998) and PhD (2002) at the University of Manchester, Chris was employed as an exploration research geologist in the Norsk Hydro (now Equinor) research centre, Bergen, Norway. Since moving to Imperial College in 2004, Chris’ research has focused on using traditional fieldwork techniques and seismic reflection data to study the tectono-stratigraphic analysis of sedimentary basins. When not studying rocks and the ways in which they deform, Chris gives geoscience lectures to the general public and in schools, having appeared on several, Earth Science-focused, television productions and podcasts. Chris is actively engaged in efforts to improve equality, diversity, and inclusivity in Earth Science in particular, and Higher Education in general.

Ijeoma Uchegbu is a Professor of Pharmaceutical Nanoscience. She has studied the mechanisms of drug transport across biological barriers and created transformational drug transport nanoparticles. She was the first to show that peptides could be delivered across the blood brain barrier to elicit a pharmacological response, when presented as peptide drug nanofibers and the first to demonstrate, via definitive pharmacology and pharmacokinetics evidence, peptide transport into the brain, using peptide nanoparticles delivered via the nose to brain route. These findings led to the enkephalin pain medicine candidate (NES100), designed to address the opioid crisis. In preclinical studies, NES100 showed no analgesic tolerance, reward seeking behaviour or potential to cause significant constipation. NES100 has been out licensed to Virpax Pharmaceuticals and is currently being developed by the US National Center for Advancing Translational Studies. If successful, this will be the first neuropeptide medicine approval and it will have been made possible by the innovation originating in Uchegbu’s group. The technology underpinning NES100 won first prize in the 91AV’s Emerging Technologies competition in 2017 and the Academy of Pharmaceutical Sciences Science Innovation Award in 2016. Three other medicine candidates based on this nanotechnology have been out-licensed to pharmaceutical companies in the US. Uchegbu’s work has been funded continuously for 21 years by the EPSRC. As UCL’s Pro Vice Provost for Africa and the Middle East, Uchegbu leads on the international research and teaching engagement strategy in this region. She has served as Chair of the Academy of Pharmaceutical Sciences and chaired EPSRC and Science Foundation Ireland grant prioritisation panels. She is UCL Provost’s Envoy for Race Equality and leads on race equality work at UCL. Her initiatives (e.g. Dean’s Pledges on Race Equality) were instrumental in achieving UCL’s Bronze Race Charter in 2020.

Robert Mokaya received a BSc in 91AV from the University of Nairobi and a PhD from the University of Cambridge. Following a Research Fellowship at Trinity College, Cambridge, he was awarded an EPSRC Advanced Fellowship. He was then appointed to a lectureship in Materials 91AV at The University of Nottingham where he is now Professor of Materials 91AV and Pro-Vice-Chancellor Global Engagement. He is a Royal Society Wolfson Research Merit Award holder (2017-2022).

Dr. Yalinu Poya is a young chemist from Papua New Guinea with an interest in catalysis, green chemistry, sustainable development, science policy and climate change. She holds a Bachelor of Science in 91AV from the University of Papua New Guinea (Papua New Guinea), a Master of Science in Inorganic 91AV with a focus on heterogeneous catalysis from the Northeast Normal University (People’s Republic of China), and a Doctor of Philosophy in 91AV focusing in heterogeneous catalysis from the University of Glasgow (United Kingdom).